ArTara Therapeutics, Inc. (TARA)
| Market Cap | 214.26M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.78M |
| Shares Out | 6.32M |
| EPS (ttm) | -6.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $18.99 |
| Previous Close | $19.11 |
| Change ($) | -0.12 |
| Change (%) | -0.63% |
| Day's Open | 19.11 |
| Day's Range | 18.76 - 19.48 |
| Day's Volume | 60,240 |
| 52-Week Range | 16.76 - 60.70 |
There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they believe they can profit remarkably from their investments after the market has...
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare disease...
NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare disease...
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare disease...
- On T rack to Complete GMP Batch Runs in Mid-2021 to C onfirm C omparability B etween TARA-002 and OK-432 - - Expect to I nitiate Phase 1 T rial for TARA-002 in P atients with N on- M uscle I...
NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare disease...
NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare disease...
NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare dise...
NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare dise...
- Company Demonstrates Initial Comparability Between TARA-002 and OK-432, Advancing to Final GMP Comparability Runs -
About TARA
Protara Therapeutics, a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therap... [Read more...]
| Industry Biotechnology | |
| CEO Jesse Shefferman | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol TARA |
Analyst Forecasts
According to 3 analysts, the average rating for TARA stock is "Strong Buy." The 12-month stock price forecast is 45.67, which is an increase of 140.49% from the latest price.